Question follow-through · 87680

Drugs: VAT

To ask the Chancellor of the Exchequer, whether she has made an assessment of the potential impact of introducing VAT to to medicines provided free under Early Access Medicines Scheme programmes on pharmaceutical companies.

answeredTreasury

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Treasury
Tabled
3 Nov 2025
Target answer date
11 Nov 2025
Answer
11 Nov 2025 · 8 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Recorded timeline

  1. 3 Nov 2025

    Question tabled

    To ask the Chancellor of the Exchequer, whether she has made an assessment of the potential impact of introducing VAT to to medicines provided free under Early Access Medicines Scheme programmes on pharmaceutical companies.

  2. 11 Nov 2025

    Target answer date

    Date supplied by the official written-questions record.

  3. 11 Nov 2025

    Answer published

    I refer the honourable member to the answer that I gave to PQ UIN: 87051.

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Internet: Outages

25 Nov 2025 · To ask the Chancellor of the Exchequer, what estimate her Department has made of the cost to the economy of recent outages of large-scale cloud providers.

Strong linkSame MP, department and exact heading

Drugs: VAT

4 Feb 2026 · To ask the Chancellor of the Exchequer, whether her Department has directed HMRC to review the application of VAT upon medicines supplied free-of-charge via EAMS and other compassionate access schemes.